172 related articles for article (PubMed ID: 27072691)
21. LpxC inhibition: Potential and opportunities with carbohydrate scaffolds.
Amudala S; Sumit ; Aidhen IS
Carbohydr Res; 2024 Mar; 537():109057. PubMed ID: 38402732
[TBL] [Abstract][Full Text] [Related]
22. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC.
Barb AW; Leavy TM; Robins LI; Guan Z; Six DA; Zhou P; Hangauer MJ; Bertozzi CR; Raetz CR
Biochemistry; 2009 Apr; 48(14):3068-77. PubMed ID: 19256534
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups.
Pirrung MC; Tumey LN; Raetz CR; Jackman JE; Snehalatha K; McClerren AL; Fierke CA; Gantt SL; Rusche KM
J Med Chem; 2002 Sep; 45(19):4359-70. PubMed ID: 12213077
[TBL] [Abstract][Full Text] [Related]
24. Activation of Escherichia coli UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase by Fe2+ yields a more efficient enzyme with altered ligand affinity.
Hernick M; Gattis SG; Penner-Hahn JE; Fierke CA
Biochemistry; 2010 Mar; 49(10):2246-55. PubMed ID: 20136146
[TBL] [Abstract][Full Text] [Related]
25. Molecular recognition by Escherichia coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase is modulated by bound metal ions.
Hernick M; Fierke CA
Biochemistry; 2006 Dec; 45(49):14573-81. PubMed ID: 17144651
[TBL] [Abstract][Full Text] [Related]
26. LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase) inhibitors: A long path explored for potent drug design.
Kumar Pal S; Kumar S
Int J Biol Macromol; 2023 Apr; 234():122960. PubMed ID: 36565833
[TBL] [Abstract][Full Text] [Related]
27. Crystal structure of LpxC from Pseudomonas aeruginosa complexed with the potent BB-78485 inhibitor.
Mochalkin I; Knafels JD; Lightle S
Protein Sci; 2008 Mar; 17(3):450-7. PubMed ID: 18287278
[TBL] [Abstract][Full Text] [Related]
28. Crystal structure of A. aeolicus LpxC with bound product suggests alternate deacetylation mechanism.
Miller MD; Gao N; Ross PL; Olivier NB
Proteins; 2015 Sep; 83(9):1706-19. PubMed ID: 26177919
[TBL] [Abstract][Full Text] [Related]
29. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
30. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
Cuny GD
Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
Gao N; McLeod SM; Hajec L; Olivier NB; Lahiri SD; Bryan Prince D; Thresher J; Ross PL; Whiteaker JD; Doig P; Li AH; Hill PJ; Cornebise M; Reck F; Hale MR
Protein Expr Purif; 2014 Dec; 104():57-64. PubMed ID: 25240855
[TBL] [Abstract][Full Text] [Related]
32. Antibacterial activities and characterization of novel inhibitors of LpxC.
Clements JM; Coignard F; Johnson I; Chandler S; Palan S; Waller A; Wijkmans J; Hunter MG
Antimicrob Agents Chemother; 2002 Jun; 46(6):1793-9. PubMed ID: 12019092
[TBL] [Abstract][Full Text] [Related]
33. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
Zhou P; Hong J
Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
[TBL] [Abstract][Full Text] [Related]
34. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
[TBL] [Abstract][Full Text] [Related]
35. Catalytic mechanism and molecular recognition of E. coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase probed by mutagenesis.
Hernick M; Fierke CA
Biochemistry; 2006 Dec; 45(51):15240-8. PubMed ID: 17176046
[TBL] [Abstract][Full Text] [Related]
36. LpxC inhibitors: a patent review (2010-2016).
Kalinin DV; Holl R
Expert Opin Ther Pat; 2017 Nov; 27(11):1227-1250. PubMed ID: 28742403
[TBL] [Abstract][Full Text] [Related]
37. Binding of uridine 5'-diphosphate in the "basic patch" of the zinc deacetylase LpxC and implications for substrate binding.
Gennadios HA; Christianson DW
Biochemistry; 2006 Dec; 45(51):15216-23. PubMed ID: 17176043
[TBL] [Abstract][Full Text] [Related]
38. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
[TBL] [Abstract][Full Text] [Related]
39. UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase functions through a general acid-base catalyst pair mechanism.
Hernick M; Gennadios HA; Whittington DA; Rusche KM; Christianson DW; Fierke CA
J Biol Chem; 2005 Apr; 280(17):16969-78. PubMed ID: 15705580
[TBL] [Abstract][Full Text] [Related]
40. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
Yamada Y; Takashima H; Walmsley DL; Ushiyama F; Matsuda Y; Kanazawa H; Yamaguchi-Sasaki T; Tanaka-Yamamoto N; Yamagishi J; Kurimoto-Tsuruta R; Ogata Y; Ohtake N; Angove H; Baker L; Harris R; Macias A; Robertson A; Surgenor A; Watanabe H; Nakano K; Mima M; Iwamoto K; Okada A; Takata I; Hitaka K; Tanaka A; Fujita K; Sugiyama H; Hubbard RE
J Med Chem; 2020 Dec; 63(23):14805-14820. PubMed ID: 33210531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]